natgillin/translations-raw huggingface dataset:
The isolated nucleic acid of claim 9, which is a self-replicating RNA molecule. An immunogenic composition comprising the self-replicating RNA molecule of claim 10 and optionally, an RNA delivery system. The immunogenic composition of claim 7, 8 or 11 for use as a medicament. 
Izolirana nukleinska kiselina u skladu s patentnim zahtjevom 6, naznačena time što je samoreplicirajuća molekula RNA. Imunogeni pripravak, naznačen time što sadrži samoreplicirajuću molekulu RNA u skladu s patentnim zahtjevom 7 i, izborno, sustav za unos RNA.
The locking nail system according to any of claims one to eleven, wherein the through holes (15,16) of the nail (1) permit the subtalar joint to be arthrodesed by means of the calcaneus-talar screws (2). 
Sustav čavla sa zaključavanjem prema bilo kojem od zahtjeva 1 do 9, pri čemu prolazne rupe (15, 16) čavla (1) omogućuju da se na subtalarnom zglobu izvrši artrodeza pomoću kalkaneus-talus vijaka (2).
The following compounds were synthesized according to the above procedure. 
Sljedeće spojeve sintetizira se postupkom opisanim gore. o
The process of claim 3, wherein step (i) comprises combining the compound of formula 1 and benzyl chloroformate. 
Postupak u skladu s patentnim zahtjevom 9, naznačen time, da korak (1) obuhvaća kombiniranje spoja formule 1 i benzil kloroformata.
The pharmaceutical composition of any of claims 14 - 16 for use in the treatment of precancerous lesions, dysplasias, metaplasias and tumor diseases, optionally including malignant neoplasias and metastasis. 
Farmaceutski pripravak u skladu s bilo kojim od patentnih zahtjeva 14 do 16, naznačen time što je namijenjen upotrebi u liječenju prekanceroznih lezija, displazija, metaplazija i tumorskih bolesti, što može uključivati zloćudne novotvorine 1 metastaze.
condensing a compound of Formula XX 
Spoj čija je Formula VI:
a container that contains a pharmaceutical composition containing a peptide according to any one of claims 1 to 3, the nucleic acid or the expression vector according to claim 4, a cell according to claim 6 or 7, or an activated cytotoxic T lymphocyte according to claim 10, in solution or in lyophilized form; and 
posudu koja sadrži farmaceutski sastav koji sadrži peptid u skladu s bilo kojim od patentnih zahtjeva od 1 do 3, nukleinskom kiselinom ili vektorom ekspresije u skladu s patentnim zahtjevom 4, stanicom u skladu s patentnim zahtjevom 6 ili 7 ili aktiviranim citotoksičnim T limfocitom u skladu s patentnim zahtjevom 10, u otopini ili u liofiliziranom obliku; te
A combination consisting essentially of the B-lactamase inhibitor: 
Kombinacija koja se u osnovi sastoji od inhibitora B-laktamaze: o "i
treating compound formula (B) with acid in suitable solvent in order to depart the aldehyde group from compound formula (B) to obtain rivaroxaban of formula (I). 
tretiranja spoja formule (B) s kiselinom u prikladnom otapalu tako da aledhidna skupina napusti spoj formule (B) kako bi se dobio rivaroksaban formule (1). [image]
The method according to claim 3, wherein said finishing step consists in removing at least part of the portions (18a, 18b, 18c, 131a, 131b, 131c, 131d) of the element (18), or of the localized elements (130a, 130b, 130c, 130d) which emerge from the ground contact surfaces (25, 125) of the tread. 
Postupak prema zahtjevu 3, naznačen time, da se spomenuti završni korak sastoji u uklanjanju barem dijela odjeljaka (18a, 18b, 18c, 1314, 131b, 131c, 131d) od elementa (18), ili od lokaliziranih elemenata (130a, 130b, 130c, 130d) koji izbijaju iz površina od gazišta za kontakt s tlom (25, 125).
Generally, component (III) comprises at least four amino acid residues, preferably at least 10 additional amino acid residues, more preferably at least 20, or at least 30. 
Fuzijski peptid prema patentnom zahtjevu 9, naznačen time da komponenta (Ill) obuhvaća najmanje četiri aminokiselinska ostatka, ili poželjno obuhvaća najmanje 10 aminokiselinskih ostataka, ili još poželjnije obuhvaća najmanje 20 aminokiselinskih ostataka,
A process for making a monolithic intravaginal ring, the process comprising: 
Postupak za izradu monolitnog intravaginalnog prstena u skladu s patentnim zahtjevom 1, naznačen time, da postupak obuhvaća:
(m-2) adding water and an alcohol selected from methanol, ethanol, isopropanol and n-propanol and allowing crystallisation of the compound of the Formula X to occur, collecting the compound of the Formula X and washing the compound of the Formula X with a mixture of water and the alcohol selected from methanol, ethanol, isopropanol and n-propanol, followed by a solvent selected from ethyl acetate, butyl acetate and acetonitrile at a temperature in the range of from 25 to 55°C; and whereafter the compound of the Formula X obtained in the form of the free 
C; ili (m-2) dodavanja vode i alkohola izabranog od metanola, etanola, izopropanola i n-propanola i dozvoljavanja kristalizacije spoja formule X, i sakupljanja spoja formulom X i pranja spoja sa formulom X sa mješavinom vode i alkohola izabranog od metanola, etanola, izopropanola i n-propanola, a nakon toga sa otapalom izabranim između 20
A pharmaceutical composition comprising the antibody according to any one of claims 1 to 14, the immunoconjugate according to claim 18, or the bispecific or multispecific molecule according to claim 19 and a pharmaceutically acceptable carrier. 
Farmaceutski pripravak koji sadrži protutijelo prema bilo kojem od zahtjeva 1 do 12, imunokonjugat prema zahtjevu 13, ili bispecifična ili multispecifična molekulu prema zahtjevu 14 i farmaceutski prihvatljivi nosač.
The matches are located crosswise the box. 
Å ibice se nalaze poprijeko kutije.
Compounds according to one or more of Claims 1-5 in which in which 
Spojevi prema jednom ili više zahtjeva 1-5 naznačeni time da
is hydrogen or —CO-Aaa; Aaa is an amino acid residue Thr or Ser; a C-terminus thereof is a free terminus, is amidated or is esterified; 
R, je vodik ili -CO-Aaa; Aaa je aminokiselinski ostatak, kojeg se bira između Thr i Ser; gdje je njegov C-kraj slobodni kraj, amidiran ili esterificiran;
reacting Compound (D) or a pharmaceutically acceptable salt thereof with H2 in the presence of a Pd catalyst on carbon (Pd(0)/C) to form a HCl salt of Compound (F) 
OR CbzHN, Â«DO. (D reakciji Spoja (D), ili njegove farmaceutski prihvatljive soli, s H2, u prisutnosti Pd katalizatora na ugljiku
In like manner to that described in Examples 2, 3 and 7, the following cis-isomeric compounds were prepared from the appropriate substituted benzophenones and, in certain instances, resolved into their enantiomeric forms: 
Na sličan način sa onim koji je opisan u primjerima 2, 3 i 7, napravljeni su sljedeći cis-izomerni spojevi iz odgovarajućih supstituiranih benzofenona i, u izvjesnim slučajevima razloženi su u enantiomerne oblike:
The antibody or antibody fragment for use according to claim 16, wherein the use is for the treatment of cancer. 
Antitijelo ili fragment antitijela prema patentnim zahtjevima 1 do 12 za uporabu u postupku za liječenje kancera. 9 e
A compound or pharmaceutically acceptable salt thereof according to claim 1, wherein the compound is selected from -[3-[(3S)-4-(3-chloro-4-fluoro-phenyl)-3-methyl-piperazin-1-yl]-2-methyl-3-oxo-propyl]-5-cyclopropyl-imidazolidine-2,4-dione, 
Spoj ili njegova farmaceutski prihvatljiva sol u skladu s patentnim zahtjevom 1, naznačen time, da je spoj odabran od -[3-[(3S)-4-(3-kloro-4-fluoro-fenil)-3-metil-piperazin-1-il]-2-metil-3-okso-propil]-5-ciklopropil-imidazolidin-2,4-diona,
In another aspect, the teaching relates to a method for determining an immune response in a subject, comprising determining T cells reactive with a peptide of the teaching or a cell of the teaching presenting a peptide of the teaching or a procession product thereof in a biological sample isolated from the subject. 
Postupak za određivanje imunološkog odgovora kod subjekta, koji obuhvaća određivanje T stanica reaktivnih s peptidom sukladno patentnom zahtjevu 1 ili 2 u biološkom uzorku izoliranom od subjekta.
Preferably, it is fused to heavy chain regions, like the CH2 and CH3 domains of human IgG1, for example. 
Poželjno, fuzioniran je za teški lanac poput na primjer domena CH2 i CH3 ljudskog IgGl.
The formulation for use in treating a disease or disorder according to claim 15 or 16, wherein said disease or disorder associated with reduced endogenous testosterone production is hypogonadism. 
Formulacija za tretman bolesti ili poremećaja prema zahtjevu 15 ili 16, naznačena time, da navedena bolest ili poremećaj povezan sa smanjenom endogenom proizvodnjom testosterona je hipogonadizam.
Finally, in Fig. 18.1 to 18.3, the conventional process is compared with the novel process as schematically illustrated in Fig. 19.1 to 19.2. 
Na kraju, na slikama 18.1 do 18.3 je konvencionalni postupak uspoređen s novim postupkom koji je shematski prikazan na slikama 19.1 do 19.2.
The use of any one of claims 9 to 12, wherein the antibody or antigen-binding fragment thereof comprises a variable heavy chain (VH) and a variable light chain (VL), wherein the heavy chain variable region comprises the amino acid sequence of SEQ ID NO: 164 and the light chain variable region comprises the amino acid sequence of SEQ ID NO: 87. 
Imunovezno sredstvo prema zahtjevu 28, naznačeno time, da varijabilno područje jakog lanca obuhvaća aminokiselinsku sekvencu od SEQ ID NO:164, a varijabilno područje slabog lanca obuhvaća aminokiselinsku sekvencu od SEQ ID NO:87.
The construct for the use of claim 3, wherein 5µg per square meter patient body surface area are to be administered at the first day(s) of the infusion period, followed by administration of 15µg per square meter patient body surface area as daily dose for the remaining period. 
Konstrukt namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 13, naznačen time što CD19xCD3 bispecifično jednolančano protutijelo kao konstrukt treba primijeniti u dnevnoj dozi od 15 µg, 30 µg, 60 µg ili 90 µg/m2 tjelesne površine pacijenta.
Finally, the coating obtained is sprayed onto the surfaces of the tablet cores and dried. Film-coated tablet containing drospirenone active agent, comprising a tablet core coated with a film-forming polymer layer with improved resistance against atmospheric humidity wherein the tablet core is obtainable by a process which comprises dissolving drospirenone in ethanol, then dripping continuously or periodically the solution obtained onto the surface of the fluid bed in a fluidizing equipment without spraying pressure while controlling the temperature of the product obtained and removing the solvent molecules from the wet material by a hot airflow; 
Postupak proizvodnje filmom obloženih tableta koje sadrže drospirenon kao aktivni sastojak, naznačen time, da obuhvaća otapanje drospirenona u etanolu, zatim kontinuirano ili periodično kapanje dobivene otopine na površinu fluidne podloge u fluidiziranoj opremi bez tlaka pulverizacije, prilikom čega se kontrolira temperatura dobivenog proizvoda odstranjujući molekule otopine iz vlažnog materijala pomoću vrućeg zračnog strujanja, te se dobivene jezgre oblažu filmom s organskom i/ili vodenom otopinom ili se raspršuje polimer koji tvori film.
is hydrogen, methyl, chloro, or fluoro; or a pharmaceutically acceptable salt thereof. 
R* je vodik, metil, klor ili fluor; ili njegova farmaceutski prihvatljiva sol.
Concentration of the eluant yielded the ammonium salt of Compound 1 (947 mg, 5.38 mmol, 75% yield) as a white solid. 
Koncentriranjem eluenta dobivena je amonijeva sol Spoja 1 (947 g, 5.38 mmol, 75% prinosa) kao bijela krutina.
The at least two peptides/fragments in the vaccine of the present invention are preferably formulated with an adjuvant, preferably aluminum hydroxide. 
Cjepivo prema bilo kojem od zahtjeva 1 do 7, naznačeno time, da cjepivo obuhvaća najmanje jedno pomoćno sredstvo, poželjno aluminijev hidroksid.
Process according to one of the claims 1 to 9, wherein the at least one water-soluble acid provided in step b) is added in one or more steps, preferably in one step to said aqueous calcium carbonate containing mineral slurry. 
Postupak prema jednom od zahtjeva 1 do 8, naznačen time da se barem one kiselina koja se otapa u vodi osigurana u koraku b) dodaje u jednom ili više koraka, poželjno u jednom koraku u navedenu vodenu suspenziju koja sadrži kalcijev karbonat.
a main surface 50 comprising an opening and side edges extending to the main surface and defining the perimeter thereof and 
- < glavnu površinu (50) koja sadrži otvor i bočne rubove koji se protežu do navedene glavne površine 1 definiraju njen perimetar;
Plant according to claim 1, wherein seen in longitudinal direction of the stem of the plant, the hole extends at least in a direction away from the roots of the plant. 
Postupak prema zahtjevu 2, naznačen time da se veličina početnog otvora (IH) proširuje barem u smjeru udaljenom od korijena (RS) biljke (P).
It is therefore advantageous to have a formulation wherein the average density of the floccules (comprising the micronised B2-agonist, micronised corticosteroid and moisture-scavenger excipient) is substantially the same as the density of the propellant ±0.2 g/cm3, preferably ±0.1 gcm3, more preferably ±0.05 g/cm3 of the propellant. 
Medicinska aerosolna suspenzijska formulacija u skladu s patentnim zahtjevom 1, naznačena time što je prosječna gustoća pahuljica ista kao gustoća pogonskog plina + 0,1 g/cm*; po mogućnosti + 0,05 g/em'.
cotton wool, porous graphitized carbon solid phase extraction (PGC-SPE), cationic exchange resins, liquid-liquid extraction or a mixture of the foregoing 
vate, čvrsto fazne ekstrakcije poroznog grafitiziranog ugljika (PGC-SPE - porous graphitized carbon solid phase extraction), kationskih izmjenjivačkih smola, tekuće-tekuće ekstrakcije ili mješavine gore navedenog
represents hydrogen or bromine; 
R6 predstavlja vodik ili brom;
The composition of claim 1 or 2, wherein said porogen hydrogel or said bulk hydrogel comprises a bioactive factor for use in muscle repair, regeneration, or formation. The composition of claim 12, wherein 
Pripravak u skladu s patentnim zahtjevom 1 ili 2, naznačen time što navedeni porogeni hidrogel ili navedeni volumni hidrogel sadrži bioaktivni čimbenik, namijenjen upotrebi u obnovi, regeneriranju ili stvaranju mišića.
The process according to claim 10, wherein said co-catalyst is an organo-oxygenated compound of an element M′ different from carbon and belonging to groups 13 or 14 of the Periodic Table of the Elements. 
Postupak u skladu s patentnim zahtjevom 11, naznačen time što se navedeni sukatalizator bira između organo-oksigeniranih spojeva elementa M’ koji nije ugljik koji pripada skupinama 13 ili 14 u Periodnoj tablici elemenata, poput aluminoksana opće formule (IV):
Printing sheet according to any of the preceding claims, wherein at least 10% of the dry weight of the binder part and preferably not more than 90% is constituted by waterglass, wherein preferably % - 80%, preferably 50% - 70% of the dry weight of the binder part is constituted by waterglass, and wherein the remainder of the binder part is constituted by another binder, preferably selected from the group consisting of latex, in particular styrene-butadiene, styrene-butadiene-acrylonitrile, carboxylated styrene-butadiene, styrene-acrylic, styrene-butadiene-acrylic latexes, starch, polyacrylate salt, polyvinyl alcohol, soy, casein, carboxymethyl cellulose, starch, hydroxymethyl cellulose and mixtures thereof; 
List papira za ispis prema bilo kojem od prethodnih zahtjeva, naznačen time da najmanje 10% mase suhe tvari vezivnog dijela i poželjno ne više od 90% čini vodeno staklo, pri čemu poželjno 45% - 80%, poželjno 50% - 70% mase suhe tvari od vezivnog dijela čini vodeno staklo, te pri čemu oslalak vezivnog dijela čini druga vezivna tvar, poželjno odabrana iz skupine koju čine lateks, naročilo stiren-butadien, stiren-butadien-akrilonitril, karboksilirani stiren-butadien, stiren-akril, stiren-butadien-akrilni lateksi, škrob, poliakrilna sol, polivinil alkohol, soja, kazein, karboksimetil celuloza, škrob, hidroksimetil celuloza i njihove mješavine; ili pri čemu poželjno je u osnovi vezivni dio u cijelosti sačinjen od vodenog stakla, te pri čemu se vodeno staklo može nadopuniti sa dodacima i/ili može biti kemijski izmijenjeno.
The edges of the inside side walls are attached to the inside front wall. 
Rubovi unutarnjih bočnih zidova pričvršćeni su na unutarnji prednji zid.
The compound of claim 1 selected from: and pharmaceutically acceptable salts and solvates thereof. 
O i njegovih farmaceutski prihvatljivih soli i solvata. Spoj prema zahtjevu 1 izabran od:
The anti-CTLA-4 antibody and 2'-deoxy-2',2'-difluorocytidine monohydrochloride (B-isomer), or pharmaceutically acceptable salt, solvate, or hydrate thereof, for the use according to any one of Claims 1 to 8, wherein said cancer treatment further comprises an anti-proliferative cytotoxic agent either alone or in combination with radiation therapy. 
Anti-CTLA-4 antitijelo i 4'-Demetilpipodofilotoksin 9-[4,6-O-(R)-etiliden-B-D-glukopiranazid], 4'-(dihidrogen fosfat) ili njegova farmaceutski prihvatljiva sol, solvat, ili hidrat, za primjenu prema bilo kojem od patentnih zahtjeva 1 do 8, gdje navedeno liječenje raka dalje sadrži anti-proliferativni citotoksični agens ili sam ili u kombinaciji sa radioterapijom.
measuring the oxygen content of an exhaust gas from the oxidation catalyst using an oxygen sensor, and using this information to modulate an air input to the catalyst or to the chamber or to both the catalyst and the chamber so as to maintain the oxygen level of a gas exiting a waste treatment apparatus comprising the chamber and the catalyst; and 
- - mjerenje sadržaja kisika u ispušnom plinu iz katalizatora pomoću osjetnika kisika i korištenje tih podataka za moduliranje dovoda zraka u katalizator ili u komoru ili i u katalizator i u komoru, kako bi se održavala razina kisika u plinu koji izlazi iz uređaja; i
These are for example fatty acids with either hydroxy-, epoxy or acrylate groups attached to the carbon chain of the fatty acid. 
To su, na primjer, masne kiseline s hidroksi, epoksi ili akrilatnim skupinama povezanim na ugljikov lanac masne kiseline.
n is 0-2; or a pharmaceutically acceptable salt thereof. A compound of claim 2, wherein A is a 5-membered heterocyclic ring, which may contain 0-2 double bonds and may be substituted by 1 to 3 groups selected from the group consisting of C1-C6alkyl, substituted C1-C6alkyl, C3-C7cycloalkyl, halo, hydroxyl, oxo, amide, carboxylic acid, -C(O)Ra, -SO2Ra, arylalkyl, -(C1-C3alkyl)aryloxy, aryl, heteroaryl and C1-C4alkoxy, in which each Ra is independently C1-C6alkyl, substituted C1-C6alkyl or unsubstituted C3-C7cycloalkyl; 
Spoj u skladu s patentnim zahtjevom 2, naznačen time što je A 5-eročlani heterociklički prsten, koji može sadržavati 0-2 dvostruke veze i može biti supstituiran s 1 do 3 skupine, koje se bira iz skupine koju čine C;-Cgalkil, supstituirani C;-Cgalkil, C3-Czcikloalkil, halogen, hidroksil, okso, amid, karboksilna kiselina, -C(O)R,, -SO>R., arilalkil, (C;-C;alkiljariloksi, aril, heteroaril i C;-Cgalkoksi, gdje je svaki R, neovisno C;-CÂ«alkil, supstituirani C;- Csalkil ili nesupstituirani C2-Crcikloalkil; svaki R> i R3 je neovisno vodik, C,-Cgalkil, supstituirani C,-Cgalkil, halogen, hidroksil, amid, karboksilna kiselina ili C,-C,alkoksi;
A polymorphic crystalline form of a compound of Formula I: 
PATENTNI ZAHTJEVI Kristalni polimorf koji sadrži spoj Formule I:
Thus, decolourisation of caramelised feedstock in accordance with the invention produces a material with a significantly higher absorption ratio A280/560 than ordinary caramels that have been produced by caramelisation in the presence of a nitrogen source (notably ammonia caramel and sulphite ammonia caramel). 
Dakle, obezbojenjem karamelizirane sirovine u skladu s izumom se proizvodi materijal sa značajno višim apsorpcijskim omjerom A»go;sgo Od običnih karamela koje su proizvedene karamelizacijom u prisutnosti izvora dušika (osobito amonij karamele i sulfit amonij karamele).
The injectable depot composition according to claim 1, wherein the composition is a sterile composition. 
Sastav ijednog od bilo kojeg prethodnog patentnog zahtjeva koji je sterilni sastav.
The blender system of claim 7 wherein the openings on the lid are positioned on a portion of the lid. 
Sustav mješalice prema zahtjevu 14, naznačen time, što se otvori (1501, 1601, 1602) na poklopcu nalaze najednom dijelu poklopca.
valve means (6) comprising at least one shut-off member and located in said axial conduit to block said drilling mud and stop its flow from said upstream end (2a) to said downstream end (2b); 
– ventilno sredstvo (6), koje ima najmanje jedan zatvarački element i koje se nalazi u navedenom aksijalnom vodu radi blokiranja navedene isplake i zaustavljanja njezinog protoka od navedenog uzvodnog kraja (2a) do navedenog nizvodnog kraja (2b);
Through the process object of this invention it is, moreover, possible to prepare ureic resins in the solid state, which once dispersed in water may give place to foams that together with the advantages already known from foams obtained starting from solid resins (good mechanical resistance, good stability through time), have the advantage of expelling very little formaldehyde during the drying phase. 
Sa postupkom, koji je predmet ovog izuma, možemo pored toga pripremiti urinske smole u čvrstom stanju, iz kojih mogu, poslije dispergiranja u vodi, stvoriti se pjene, koje imaju već uz poznate prednosti pjena, izrađenih iz čvrstih smola (dobra mehanička čvrstoća, dobra vremenska postojanost) još i prednost, da u stupnju sušenja emitiraju vrlo malo formaldehida,
Method according to claim 6 or 7, wherein the acid is hydrochloric acid. 
Postupak prema zahtjevu 6 ili 7, naznačen time da kiselina je klorovodična kiselina.
wherein the fusion peptide has insulinotropic activity. The fusion peptide according to claim 1, wherein component (II) is a peptide sequence containing a sequence selected from a group consisting of SEQ ID NO.: 27, and SEQ ID No.: 28, or a sequence having at least 90% sequence identity with SEQ ID Nos.: 27 or 28. 
Fuzijski peptid prema patentnim zahtjevima 1 do 3, naznačen time da je komponenta (II) peptidna sekvenca koja sadrži sekvencu prema SEQ ID No.: 23 (RRDFPEEVAIVEEL) ili SEQ ID No. 24 (RRDFPEEVAIAEEL) ili sekvencu koja ima najmanje 80% identiteta sekvence sa SEQ ID No.: 23 ili 24.
The pavement system of claim 1, further comprising a surface layer placed over the second geocell layer or the optional capping layer, the surface layer comprising asphalt or concrete or ballast or granular material. 
Sustav kolnika prema zahtjevu 1, naznačen time što nadalje sadrži površinski sloj (100) postavljen preko prvog sloja geoćelije (80), površinski sloj (100) koji sadrži asfalt ili beton ili balast ili granulirani materijal.
Process of generating an electric current wherein melanins absorb energy obtained by light, characterized in that melanins induce and carry out a photolysis of water molecules in the presence of light, whereby high energy electrons are transferred to a primary electron acceptor, and whereby melanins are used for the reverse reaction that comprises the union of atoms of hydrogen and oxygen produced by said photolysis for generating water molecules and an electric current. 
Postupak generiranja električne struje kada melanini apsorbiraju energiju dobivenu od svjetlosti, naznačen time, da melanini induciraju i provode fotolizu molekula vode u prisutnosti svjetla, pri čemu se prenose elektroni velike energije do primarnog elektronskog prijamnika, te pri čemu se melanini upotrebljavaju za povratnu reakciju koja obuhvaća ujedinjenje atoma vodika i kisika proizvedenih pomoću navedene fotolize, u svrhu generiranja molekula vode i električne struje.
The stripping composition of claim 1, wherein the at least one high-boiling solvent is benzyl alcohol. 
Sastav za skidanje u skladu s bilo kojim od prethodnih zahtjeva, naznačen time da je najmanje jedno otapalo visokog vrelišta benzilni alkohol.